Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2020

Zhang Kai, Hong Xiaohua, Song Zhengbo, Xu Yu, Li Chengcheng, Wang Guoqiang, Zhang Yuzi, Zhao Xiaochen, Zhao Zhengyi, Zhao Jing, Huang Mengli, Huang Depei, Qi Chuang, Gao Chan, Cai Shangli, Gu Feifei, Hu Yue, Xu Chunwei, Wang Wenxian, Lou Zhenkun, Zhang Yong, Liu Li

Abstract excerpt

PURPOSE: NOTCH signaling is associated with tumorigenesis, mutagenesis, and immune tolerance in non-small cell lung cancer (NSCLC), indicating its association with the clinical benefit of immune checkpoint inhibitors (ICI). We hypothesized that NOTCH mutation in NSCLC might be a robust predictor of immunotherapeutic efficacy. EXPERIMENTAL DESIGN: Multiple-dimensional data including genomic, transcriptomic, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Drug Resistance, Neoplasm

Share to Immune Checkpoint Inhibitors

Share to Kaplan-Meier Estimate

Share to Progression-Free Survival

Share to Receptors, Notch

Source

Identifiers

PMID: 32241817
DOI: 10.1158/1078-0432.CCR-19-3976

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC.PMID 32241817Read ↗

Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.Semantic proximity Read ↗

The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.Semantic proximity Read ↗

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint InhibitorsSemantic proximity Read ↗

The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancerSemantic proximity Read ↗

Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes.Semantic proximity Read ↗

Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC.Semantic proximity Read ↗

Molecular Pathways: Context-Dependent Approaches to Notch Targeting as Cancer TherapySemantic proximity Read ↗

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Semantic proximity Read ↗

Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer.Semantic proximity Read ↗

Shedding light on the molecular determinants of response to anti-PD-1 therapy.Semantic proximity Read ↗

Notch signaling genes and CD8 + T‐cell dynamics: Their contribution to immune‐checkpoint inhibitor therapy in oral squamous cell carcinoma: A retrospective studySemantic proximity Read ↗

ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.